@article{fdi:010083179,
  title = {{E}arly combination therapy with hydroxychloroquine and azithromycin reduces mortality in 10,429 {COVID}-19 outpatients},
  author = {{M}illion, {M}. and {L}agier, {J}. {C}. and {T}issot-{D}upont, {H}. and {R}avaux, {I}. and {D}hiver, {C}. and {T}omei, {C}. and {C}assir, {N}. and {D}elorme, {L}. and {C}ortaredona, {S}{\'e}bastien and {A}mrane, {S}. and {A}ubry, {C}. and {B}endamardji, {K}. and {B}erenger, {C}. and {D}oudier, {B}. and {E}douard, {S}. and {H}ocquart, {M}. and {M}ailhe, {M}. and {P}orcheto, {C}. and {S}eng, {P}. and {T}riquet, {C}. and {G}entile, {S}. and {J}ouve, {E}. and {G}iraud-{G}atineau, {A}. and {C}haudet, {H}. and {C}amoin-{J}au, {L}. and {C}olson, {P}. and {G}autret, {P}. and {F}ournier, {P}. {E}. and {M}aille, {B}. and {D}eharo, {J}. {C}. and {H}abert, {P}. and {G}aubert, {J}. {Y}. and {J}acquier, {A}. and {H}onore, {S}. and {G}uillon-{L}orvellec, {K}. and {O}badia, {Y}. and {P}arola, {P}. and {B}rouqui, {P}. and {R}aoult, {D}.},
  editor = {},
  language = {{ENG}},
  abstract = {{W}e evaluated the age-specific mortality of unselected adult outpatients infected with {SARS}-{C}o{V}-2 treated early in a dedicated {COVID}-19 day hospital and we assessed whether the use of hydroxychloroquine ({HCQ}) + azithromycin ({AZ}) was associated with improved survival in this cohort. {A} retrospective monocentric cohort study was conducted in the day hospital of our center from {M}arch to {D}ecember 2020 in adults with {PCR}-proven infection who were treated as outpatients with a standardized protocol. {T}he primary endpoint was 6-week mortality, and secondary endpoints were transfer to the intensive care unit and hospitalization rate. {A}mong 10,429 patients (median age, 45 [{IQR} 32-57] years; 5597 [53.7%] women), 16 died (0.15%). {T}he infection fatality rate was 0.06% among the 8315 patients treated with {HCQ}+{AZ}. {N}o deaths occurred among the 8414 patients younger than 60 years. {O}lder age and male sex were associated with a higher risk of death, {ICU} transfer, and hospitalization. {T}reatment with {HCQ}+{AZ} (0.17 [0.06-0.48]) was associated with a lower risk of death, independently of age, sex and epidemic period. {M}eta-analysis evidenced consistency with 4 previous outpatient studies (32,124 patients-{O}dds ratio 0.31 [0.20-0.47], {I}-2 = 0%). {E}arly ambulatory treatment of {COVID}-19 with {HCQ}+{AZ} as a standard of care is associated with very low mortality, and {HCQ}+{AZ} improve {COVID}-19 survival compared to other regimens.},
  keywords = {{SARS}-{C}o{V}-2 ; {COVID}-19 ; {H}ydroxychloroquine ; {A}zithromycin ; {A}mbulatory ; {O}ut-patients ; {T}reatment},
  booktitle = {},
  journal = {{R}eviews in {C}ardiovascular {M}edicine},
  volume = {22},
  numero = {3},
  pages = {1063--1072},
  ISSN = {1530-6550},
  year = {2021},
  DOI = {10.31083/j.rcm2203116},
  URL = {https://www.documentation.ird.fr/hor/fdi:010083179},
}